Rafael Holdings reports Q3 FY2026 net loss of $4.2M; cash $30.5M; NDA expected H2 2026

Rafael Holdings reported third quarter fiscal 2026 results for the period ended April 30, 2026, recording a net loss attributable to the company of $4.2 million, or $0.08 per share, and holding $30.5 million in cash and cash equivalents. Revenue for the quarter was $0.18 million and research and development expenses totaled $4.9 million. Management said the pivotal Phase 3 TransportNPC trial reached last patient last visit and they expect to submit an NDA in the second half of calendar 2026.Financial HighlightsCash and cash equivalents: $30.5 million as of April 30, 2026.Quarterly revenue: $0.18 million for the three months ended April 30, 2026 (total revenue $179 thousand).Net loss attributable to Rafael Holdings: $4.2 million, or $0.08 per share, for the three months ended April 30, 2026.Year-to-date net loss attributable to Rafael Holdings: $20.5 million, or $0.40 per share, for the nine months ended April 30, 2026.Research and development expense: $4.9 million for the quarter and $16.9 million for the nine months ended April 30, 2026.Business HighlightsPivotal Phase 3 TransportNPC trial reached last patient last visit, advancing clinical understanding of Niemann-Pick Disease Type C1 (NPC1).Management reported a pre-NDA meeting with the FDA and expects to submit a New Drug Application in the second half of calendar 2026, signaling an expedited regulatory path.Acquisition of Cyclo Therapeutics (March 2025) continues to impact operations and expense consolidation, reflected in higher R&D spend and inclusion of Cyclo expenses.Company strategy focused on transitioning into a commercial-stage biotechnology company with lead candidate Trappsol Cyclo being the subject of the ongoing pivotal trial.Original SEC Filing: Rafael Holdings, Inc. [ RFL ] - 8-K - Jun. 11, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.